Biocytogen Unleashes Legions of High-Tech Mice to Lure IPO Investors
The major provider of gene-edited lab rodents gets the nod for a Hong Kong listing after abandoning a plan to float shares on Shanghai’s STAR Market Key Takeaways: Gene-edited lab…
RELATED ARTICLES
- Jiuyuan Gene seeks IPO cash for bet on weight-loss drugs
-
Akeso marks profit milestone with swift rights issue
9926.HK
-
Test results for new cancer drug take Akeso investors on wild ride
9926.HK
-
Everest Medicines eyes mRNA tumor vaccines as drug valuations rebound
1952.HK
- Sichuan Biokin chases Hong Kong listing after BSM drug deal
-
Facing revenue crisis, Ascletis Pharma tries to bulk up with obesity drugs
1672.HK
Discover hidden China stock gems in our weekly newsletter